Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 5/20 | 0.58 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.45 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.45 |
| ▸ | LSS | P48449 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | CCNC | P24863 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | FASN | P49327 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL1543080 | 1.00 | CHRNA7 (0.58) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Fumaric Acid SCHEMBL1542527 | 1.00 | CHRNA7 (0.58) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Fumaric Acid SCHEMBL1543086 | 1.00 | CHRNA7 (0.58) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Fumaric Acid SCHEMBL1542323 | 0.93 | CHRNA7 (0.49) | CHRNA7CHRNB4CHRNA3CHRNA10CHRNA9 | |
| Fumaric Acid SCHEMBL1542320 | 0.93 | CHRNA7 (0.49) | CHRNA7CHRNB4CHRNA3CHRNA10CHRNA9 | |
| SCHEMBL1542302 | 0.91 | CHRNA7 (0.69) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1542313 | 0.91 | CHRNA7 (0.69) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Abt-107 SCHEMBL1542724 | 0.85 | CHRNA7 (0.83) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Abt-107 SCHEMBL1542457 | 0.85 | CHRNA7 (0.83) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Abt-107 SCHEMBL1542455 | 0.85 | CHRNA7 (0.83) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308875-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives as .alpha.7 nAChR modulators | Abbott Laboratories (US) | 2011-04-13 | — | — | EP | disclosed |
| US-7674794-B2 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES (US) | 2010-03-09 | — | — | US | disclosed |
| US-7655657-B2 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES (US) | 2010-02-02 | — | — | US | disclosed |
| US-20080064703-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
| US-20070066592-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBVIE INC. | 2007-03-22 | — | — | US | disclosed |
| US-20070060588-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES | 2007-03-15 | — | — | US | disclosed |
| US-7160876-B2 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES (US) | 2007-01-09 | — | — | US | disclosed |
| US-20050245531-A1 | 5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1H-indole; attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease, senile dementia, AIDS dementia, Pick's Disease, dementia associated with Down's syndrome; alpha 7 nAChR ligands modulators | ABBOTT LABORATORIES | 2005-11-03 | — | — | US | disclosed |
| US-20050137184-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBVIE INC. | 2005-06-23 | — | — | US | disclosed |
| US-20050137204-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060588-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | CHRNA7 2/4885CHRNB2 12/4885CHRNA4 10/4885 |
| US-20080064703-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | IDO1, IDO2, HTR3C | CHRNA7 144/4885CHRNB2 210/4885CHRNA4 414/4885 |
| US-20050137204-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | CHRNA7 2/4885CHRNB2 12/4885CHRNA4 10/4885 |
| US-20070066592-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | CHRNA7 2/4885CHRNB2 12/4885CHRNA4 9/4885 |
| US-20050137184-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | CHRNA7 2/4885CHRNB2 12/4885CHRNA4 9/4885 |
| US-20050245531-A1 | 5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1H-indole; attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease, senile dementia, AIDS dementia, Pick's Disease, dementia associated with Down's syndrome; alpha 7 nAChR ligands modulators | CHRNA7, CHRNA6, CHRNA10 | CHRNA7 1/4885CHRNB2 6/4885CHRNA4 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.